About NextRNA
NextRNA is a Healthcare company based in Boston (United States) founded in 2020 by Leon Wert Lamas and Dominique Verhelle. NextRNA has raised $56.1 million across 2 funding rounds from investors including Jefferies, Cobro Ventures and Lightchain Capital. Its chief executive, as recorded, is Dominique Verhelle. NextRNA offers products and services including lncRNA Platform and Small Molecule Therapeutics. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Gene Therapy and RNA. Its competitors include Stoke Therapeutics, ReNAgade and EnPlusOne Bio; 3 of its 3 listed competitors have raised funding.
Company details
Developer of RNA-targeted therapeutics for multiple areas. The company is developing therapeutics by identifying the protein responsible for the ncRNA function. The high-throughput screening platform is used to discover RNA-protein interactions and screen for molecules that disrupt the disease-related ncRNA-protein interaction.
- Headquarters Boston, United States
- Founders Leon Wert Lamas, Dominique Verhelle
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nextrnatx.com
- Social LinkedIn
- Total Equity Funding$56.1M (USD)
in 2 rounds
- Latest Funding Round$46.8M (USD), Series A
Mar 2022
- InvestorsJefferies
& 6 more
Products & Services of NextRNA
NextRNA offers a comprehensive portfolio of products and services, including lncRNA Platform and Small Molecule Therapeutics.
Platform identifies and validates lncRNAs for disease treatment through small molecule development.
Inhibitors disrupt lncRNA-RBP interactions to address pathological processes in diseases.
Funding Insights of NextRNA
NextRNA has successfully raised a total of $56.1M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $46.8 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56.1M
- Total Rounds 2
- Last Round Series A — $46.8M
- First Round $9.3M
(Mar 2022)
- Investors Count 7
All 2 funding rounds of NextRNA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $9.3M | Seed | – | – | – |
| Mar 2022 | $46.8M | Series A | – | Cobro Ventures, Lightchain Capital |
7 investors in total: 7 institutional.
Investors in NextRNA
NextRNA has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Jefferies, Cobro Ventures and Lightchain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment firm backed by the Cohen family | cobroventures.com | Mclean, United States | ||
Venture capital fund focused on early-stage life science companies | lightchain-capital.com | St. Louis, United States | ||
Early-stage tech and healthcare firms are funded by Evans Capital. | evanscapital.com | Boston, United States | ||
Philanthropic assets are managed by Willett Advisors LLC. | willettadvisors.com | New York, United States | ||
Investments in technology-based startups are made by Rivas Capital. | rivascap.com | Cambridge, United States | ||
Provides access to private real estate and equity deals for wealthy investors through consultative services. | 2014 | circlesquaredalts.com | Morristown, United States | |
Merger and acquisitions advisory services are provided across multiple sectors. | 1962 | jefferies.com | New York, United States |
Investor details for NextRNA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NextRNA
22 people are tracked at NextRNA (6 in leadership, 8 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Leon Wert Lamas | Co-Founder | Leadership |
Dominique Verhelle | Co-Founder & CEO | Leadership |
Franz Gruswitz | Senior Director, RNA & Protein Sciences | Leadership |
Sean Buchanan | Director, Biology | Leadership |
Js Cleiftie | CBO & Head of Finance | Leadership |
Alejandra Raimondi | VP, Head of Biology | Leadership |
Barry Polisky | Board Member | Board & advisors |
Malcolm Salter | Board Member | Board & advisors |
Bill McKee | Board Member | Board & advisors |
Christina Henderson | Board Member | Board & advisors |
Bobby Sandage | Board Member | Board & advisors |
Carl Novina | Scientific Advisor | Board & advisors |
Juan Cubillos-Ruiz | Scientific Advisor | Board & advisors |
Rory Johnson | Scientific Advisor | Board & advisors |
Sara Lafleur | Senior Executive Assistant | Team |
Jeffrey M. Brown | Cso, Sensorium Therapeutics | Team |
Zori Vargas | Senior Research Associate I | Team |
Spencer Truesdell | Senior Research Associate II, Biology | Team |
Chris Zheng | Senior Accountant | Team |
Dorothy Brach | Senior Scientist, Biology | Team |
2 more people are available in the full profile.
Complete people profiles for NextRNA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NextRNA
2 dated milestones of NextRNA across 2 years, from founding to its latest funding, stage changes and deals.
- Founded NextRNA is founded.
- Funding First funding round of $9.3M.
Competitors of NextRNA
NextRNA has 3 listed competitors in our database, 3 of them funded. They include Stoke Therapeutics, ReNAgade and EnPlusOne Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stoketherapeutics.com | 2014 | Bedford, United States | $130.85M | 117 | Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing | |
| renagadetx.com | 2021 | Cambridge, United States | $300M | 136 | RNA-based medicines are developed for treating multiple diseases. | |
| enplusonebio.com | 2022 | Watertown, United States | $46.71M | Developer of RNA synthesis platform for gene therapeutics |
Detailed competitors of NextRNA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NextRNA
The website of NextRNA (nextrnatx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 2.9% vs previous month
Websites whose visitors overlap most with NextRNA. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| triveni.bio | 100% | 5.4K | #3,407,762 | View details | |
| cuebiopharma.com | 89% | 4.9K | #7,063,180 | View details | |
| fluentbio.com | 88% | 4.7K | #3,913,179 | View details | |
| sherlock.bio | 82% | 2.8K | #4,929,420 | View details | |
| werewolftx.com | 79% | 4.5K | #3,895,284 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for NextRNA
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as NextRNA (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nextrna
Complete news archive for NextRNA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NextRNA
NextRNA was founded in 2020 and raised its 1st funding round 2 years after it was founded.
NextRNA is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Dominique Verhelle is the CEO of NextRNA, as recorded in our data. They have also founded this company.
NextRNA is a funded company, having raised a total of $56.1M across 2 funding rounds to date. The company's 1st funding round was a Seed of $9.3M, raised on Mar 2022.
Developer of RNA-targeted therapeutics for multiple areas. The company is developing therapeutics by identifying the protein responsible for the ncRNA function. The high-throughput screening platform is used to discover RNA-protein interactions and screen for molecules that disrupt the disease-related ncRNA-protein interaction.
NextRNA's top competitors include Stoke Therapeutics, EnPlusOne Bio and ReNAgade.
NextRNA offers lncRNA Platform and Small Molecule Therapeutics.
NextRNA has 7 investors. Key investors include Jefferies, Cobro Ventures, Lightchain Capital, Circle Squared, and Evans Capital.